ID
33107
Descripción
Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B
Palabras clave
Versiones (1)
- 28/11/18 28/11/18 -
Titular de derechos de autor
GSK group of companies
Subido en
28 de noviembre de 2018
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021
Contraindications to Subsequent Vaccination
- StudyEvent: ODM
Descripción
DTPw vaccines
Descripción
GSK Biologicals' RotarixTM vaccine or its placebo
Descripción
Local registered OPV
Descripción
Relative Contraindications
Descripción
If any one of these AEs occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.
Tipo de datos
text
Descripción
DTPw vaccines
Descripción
GSK Biologicals' RotarixTM or its placebo
Descripción
Precautions for DTPw vaccines
Descripción
If any of the following events occur in temporal relation to receipt of the study vaccines, the decision to give subsequent doses of vaccine containing the pertussis component should be carefully considered. The following event were previously considered contraindications and are now considered precautions by the Advisory Committee on Immunization Practices (ACIP)
Tipo de datos
text
Descripción
DTPw-HBV vaccines should under no circumstances be administered intravenously
Similar models
Contraindications to Subsequent Vaccination
- StudyEvent: ODM